ArticleBMC cancer2010
Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Pooled it
- Pooled it
- Pooled it
- Effects of Asprosin and Role of TLR4 as a Biomarker in Endometrial Cancer.Molecules (Basel, Switzerland) · 2025Article
- Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma.Genes & diseases · 2025Review
- Pyroptosis-associated genes and tumor immune response in endometrial cancer.Discover oncology · 2024Article
- NOD1, NOD2, PYDC1, and PYDC2 gene polymorphisms in ovarian endometriosis.Frontiers in medicine · 2024Article
- Pathomorphological Manifestations and the Course of the Cervical Cancer Disease Determined by Variations in theDiagnostics (Basel, Switzerland) · 2023Article
- The role of toll-like receptors (TLRs) and their therapeutic applications in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Association of TLR4 Rs4986791 Polymorphism and TLR9 Haplotypes with Acute Myeloid Leukemia Susceptibility: A Case-Control Study of Adult Patients.Journal of personalized medicine · 2022Article
- "Iron triangle" of regulating the uterine microecology: Endometrial microbiota, immunity and endometrium.Frontiers in immunology · 2022Review
- Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.Molecular diagnosis & therapy · 2021Article
- Toll-like receptor gene polymorphisms in patients with myeloproliferative neoplasms.Molecular biology reports · 2021Article
- Toll-Like Receptors Gene Polymorphisms in Autoimmune Disease.Frontiers in immunology · 2021Review
- Endometrial cancer: a genetic point of view.Translational cancer research · 2020Article
- Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients.Genes & diseases · 2020Article
- Toll-like receptor 9 polymorphisms andWorld journal of gastrointestinal oncology · 2019Article
- Toll-like receptor 6 expression, sequence variants, and their association with colorectal cancer risk.Journal of Cancer · 2019Article
- Functional Polymorphisms and Gene Expression of TLR9 Gene as Protective Factors for Nasopharyngeal Carcinoma Severity and Progression.Journal of immunology research · 2019Article
- TLR4 Polymorphisms and Expression in Solid Cancers.Molecular diagnosis & therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer is the most common gynaecological malignancy in women of developed countries. Many risk factors implicated in endometrial cancer trigger inflammatory events; therefore, alterations in immune response may predispose an individual to disease. Toll-like receptors (TLRs) and nucleosome-binding oligomerization domain (NOD) genes are integral to the recognition of pathogens and are highly polymorphic. For these reasons, the aim of the study was to assess the frequency of polymorphic variants in TLR and NOD genes in an Australian endometrial cancer population.
methodsTen polymorphisms were genotyped in 191 endometrial cancer cases and 291 controls using real-time PCR: NOD1 (rs2075822, rs2907749, rs2907748), NOD2 (rs5743260, rs2066844, rs2066845), TLR2 (rs5743708), TLR4 (rs4986790) and TLR9 (rs5743836, rs187084).
resultsHaplotype analysis revealed that the combination of the variant alleles of the two TLR9 polymorphisms, rs5743836 and rs187084, were protective for endometrial cancer risk: OR 0.11, 95% CI (0.03-0.44), p = 0.002. This result remained highly significant after adjustment for endometrial cancer risk factors and Bonferroni correction for multiple testing. There were no other associations observed for the other polymorphisms in TLR2, TLR4, NOD1 and NOD2.
conclusionsThe variant 'C' allele of rs5743836 causes greater TLR9 transcriptional activity compared to the 'T' allele, therefore, higher TLR9 activity may be related to efficient removal of microbial pathogens within the endometrium. Clearly, the association of these TLR9 polymorphisms and endometrial cancer risk must be further examined in an independent population. The results point towards the importance of examining immune response in endometrial tumourigenesis to understand new pathways that may be implicated in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.